Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for Musculoskeletal GVHD
NCT04932564Phase 2Terminated
- Sponsor
- Tata Memorial Centre
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leflunomide in graft-versus-host disease (GVHD), sponsored by Tata Memorial Centre. Primary endpoint: Overall Objective Response Rate at 2 years. Started Sep 2023; status: terminated.
02
Drugs
leflunomide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04932564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932564.